Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL1 | P55085 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | MMP1 | P03956 | 1/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.63 |
| ▸ | BMP1 | P13497 | 1/20 | 0.60 |
| ▸ | MMP8 | P22894 | 1/20 | 0.60 |
| ▸ | MMP12 | P39900 | 1/20 | 0.60 |
| ▸ | MMP13 | P45452 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22570455 | 0.90 | ALDH1A1 (0.65) | F2RL1ALDH1A1POLBHDAC1HDAC6 | |
| SCHEMBL29016749 | 0.88 | HDAC1 (0.68) | HDAC1HDAC6HDAC8HDAC2HDAC3 | |
| SCHEMBL9663885 | 0.87 | HDAC1 (0.70) | HDAC1HDAC6HDAC8HDAC2HDAC3 | |
| SCHEMBL14490976 | 0.86 | NPC1 (0.66) | ALDH1A1MMP1HDAC1HDAC6BMP1 | |
| SCHEMBL12228278 | 0.86 | F2RL1 (0.69) | F2RL1ALDH1A1POLB | |
| SCHEMBL13903016 | 0.84 | ALDH1A1 (0.67) | F2RL1ALDH1A1POLB | |
| SCHEMBL26345977 | 0.84 | ALDH1A1 (0.67) | F2RL1ALDH1A1POLB | |
| SCHEMBL17054176 | 0.84 | ALDH1A1 (0.67) | F2RL1ALDH1A1POLB | |
| SCHEMBL20325057 | 0.83 | POLB (0.74) | F2RL1ALDH1A1POLB | |
| SCHEMBL30986878 | 0.83 | ALDH1A1 (0.65) | F2RL1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117043157-A | ERAP inhibitors | 里尔大学 | 2023-11-10 | — | — | CN | claimed |
| EP-0946478-B1 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDES, KETONES AND HYDROXAMIC ACID COMPOUNDS | AVENTIS PHARMA INC (US) | 2007-02-14 | — | — | EP | disclosed |
| EP-1688406-A2 | Polymeric resin compounds and their preparation | Aventis Pharmaceuticals Products Inc. (US) | 2006-08-09 | — | — | EP | disclosed |
| EP-1674484-A2 | Process for the solid phase synthesis of aldehydes, ketones, oximes, amines and hydroxamic acid componds | Aventis Pharmaceuticals Products Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| EP-0946478-A4 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDES, KETONES, OXIMES, AMINES AND HYDROXAMIC ACID COMPOUNDS | AVENTIS PHARM PROD INC (US) | 2004-09-08 | — | — | EP | disclosed |
| US-6710208-B2 | REACTING AN N-ALKYLATED POLYMERIC HYDROXAMIC ACID RESIN WITH AN ORGANOMETALLIC REAGENT TO LIBERATE THE KETONE | AVENTIS PHARMACEUTICALS INC. | 2004-03-23 | — | — | US | disclosed |
| EP-1359136-A2 | Polymeric resin compounds and their preparation | Aventis Pharmaceuticals Products Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20020183558-A1 | Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and alpha, beta-unsaturated carboxylic acid and aldehyde compounds | AVENTIS PHARMACEUTICALS INC. | 2002-12-05 | — | — | US | disclosed |
| EP-1089958-A4 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDE, KETONE, OXIME, AMINE, HYDROXAMIC ACID AND ALPHA,BETA-UNSATURATED CARBOXYLIC ACID AND ALDEHYDE COMPOUNDS | AVENTIS PHARM PROD INC (US) | 2002-10-09 | — | — | EP | disclosed |
| US-6392010-B1 | FLUOROPHENYL HYDROXYLAMINE RESIN | AVENTIS PHARMACEUTICALS INC. | 2002-05-21 | — | — | US | disclosed |
| EP-1089958-A2 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDE, KETONE, OXIME, AMINE, HYDROXAMIC ACID AND ALPHA,BETA-UNSATURATED CARBOXYLIC ACID AND ALDEHYDE COMPOUNDS | Aventis Pharmaceuticals Products Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| US-6133409-A | REACTING A SOLID SUPPORT-BOUND N-ALKYLATED HYDROXAMIC ACID WITH A CARBON-NITROGEN CLEAVING ORGANOMETALLIC COMPUND TO LIBERATE THE PRODUCT KETONE | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-10-17 | — | — | US | disclosed |
| WO-1999067192-A2 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDE, KETONE, OXIME, AMINE, HYDROXAMIC ACID AND α,β-UNSATURATED CARBOXYLIC ACID AND ALDEHYDE COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| EP-0946478-A1 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDES, KETONES, OXIMES, AMINES AND HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998029376-A1 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDES, KETONES, OXIMES, AMINES AND HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183558-A1 | Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and alpha, beta-unsaturated carboxylic acid and aldehyde compounds | OGDH, OXGR1, ALDH7A1 | F2RL1 3030/4885ALDH1A1 19/4885POLB 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.